BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tonelli M, Isles C, Craven T, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, West M, Packard C, Curhan GC. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 2005;112:171-8. [PMID: 15998677 DOI: 10.1161/CIRCULATIONAHA.104.517565] [Cited by in Crossref: 141] [Cited by in F6Publishing: 49] [Article Influence: 8.3] [Reference Citation Analysis]
Number Citing Articles
1 Kitada M, Kanasaki K, Koya D. Clinical therapeutic strategies for early stage of diabetic kidney disease. World J Diabetes 2014; 5(3): 342-356 [PMID: 24936255 DOI: 10.4239/wjd.v5.i3.342] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
2 Kujawa-Szewieczek A, Więcek A, Piecha G. The lipid story in chronic kidney disease: a long story with a happy end? Int Urol Nephrol 2013;45:1273-87. [PMID: 23054316 DOI: 10.1007/s11255-012-0296-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
3 Marino A, Tannock LR. Role of dyslipidemia in patients with chronic kidney disease. Postgrad Med 2013;125:28-37. [PMID: 23842535 DOI: 10.3810/pgm.2013.07.2676] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
4 Athyros VG, Hatzitolios AI, Karagiannis A, Savopoulos C, Katsiki N, Tziomalos K, Papagianni A, Kakafika A, Gossios TD, Mikhailidis DP; IMPERATIVE Collaborative Group. IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis. Arch Med Sci 2011;7:984-92. [PMID: 22328881 DOI: 10.5114/aoms.2011.26610] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
5 Okumura S, Sakakibara M, Hayashida R, Jinno Y, Tanaka A, Okada K, Hayashi M, Ishii H, Murohara T. Accelerated decline in renal function after acute myocardial infarction in patients with high low-density lipoprotein-cholesterol to high-density lipoprotein-cholesterol ratio. Heart Vessels 2014;29:7-14. [PMID: 23358876 DOI: 10.1007/s00380-012-0321-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
6 Johns BR, Pao AC, Kim SH. Metabolic syndrome, insulin resistance and kidney function in non-diabetic individuals. Nephrol Dial Transplant 2012;27:1410-5. [PMID: 21908415 DOI: 10.1093/ndt/gfr498] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
7 Paul J, Dasgupta S, Ghosh MK, Shaw K, Roy KS, Niyogi SM. A study of atherosclerosis in patients with chronic renal failure with special reference to carotid artery intima media thickness. Heart Views 2012;13:91-6. [PMID: 23181176 DOI: 10.4103/1995-705X.102147] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
8 Hung CC, Tsai JC, Kuo HT, Chang JM, Hwang SJ, Chen HC. Dyslipoproteinemia and impairment of renal function in diabetic kidney disease: an analysis of animal studies, observational studies, and clinical trials. Rev Diabet Stud 2013;10:110-20. [PMID: 24380087 DOI: 10.1900/RDS.2013.10.110] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
9 Johns BR, Pao AC, Kim SH. Metabolic syndrome, insulin resistance and kidney function in non-diabetic individuals. Nephrol Dial Transplant. 2012;27:1410-1415. [PMID: 21908415 DOI: 10.1093/ndt/gfr7498] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Zuo Y, Yancey P, Castro I, Khan WN, Motojima M, Ichikawa I, Fogo AB, Linton MF, Fazio S, Kon V. Renal dysfunction potentiates foam cell formation by repressing ABCA1. Arterioscler Thromb Vasc Biol. 2009;29:1277-1282. [PMID: 19667109 DOI: 10.1161/atvbaha.109.188995] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
11 Asakawa T, Hayashi T, Tanaka Y, Joki N, Hase H. Changes over the last decade in carotid atherosclerosis in patients with end-stage kidney disease. Atherosclerosis 2015;240:535-43. [PMID: 25957119 DOI: 10.1016/j.atherosclerosis.2015.04.784] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
12 Kendrick J, Shlipak MG, Targher G, Cook T, Lindenfeld J, Chonchol M. Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study. Am J Kidney Dis 2010;55:42-9. [PMID: 19932541 DOI: 10.1053/j.ajkd.2009.09.020] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 3.0] [Reference Citation Analysis]
13 Takazakura A, Sakurai M, Bando Y, Misu H, Takeshita Y, Kita Y, Shimizu A, Hayakawa T, Kato K, Kaneko S, Takamura T. Renoprotective effects of atorvastatin compared with pravastatin on progression of early diabetic nephropathy. J Diabetes Investig 2015;6:346-53. [PMID: 25969721 DOI: 10.1111/jdi.12296] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
14 Marenzi G, Cabiati A, Assanelli E. Chronic kidney disease in acute coronary syndromes. World J Nephrol 2012; 1(5): 134-145 [PMID: 24175251 DOI: 10.5527/wjn.v1.i5.134] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
15 Erickson KF, Japa S, Owens DK, Chertow GM, Garber AM, Goldhaber-Fiebert JD. Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease. J Am Coll Cardiol 2013;61:1250-8. [PMID: 23500327 DOI: 10.1016/j.jacc.2012.12.034] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 4.3] [Reference Citation Analysis]
16 Choudhury D, Tuncel M, Levi M. Disorders of lipid metabolism and chronic kidney disease in the elderly. Semin Nephrol 2009;29:610-20. [PMID: 20006793 DOI: 10.1016/j.semnephrol.2009.07.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
17 Yamamoto S, Kon V. Mechanisms for increased cardiovascular disease in chronic kidney dysfunction. Curr Opin Nephrol Hypertens 2009;18:181-8. [PMID: 19374004 DOI: 10.1097/mnh.0b013e328327b360] [Cited by in Crossref: 36] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
18 Jhee JH, Joo YS, Park JT, Yoo TH, Park SK, Jung JY, Kim SW, Oh YK, Oh KH, Kang SW, Choi KH, Ahn C, Han SH. Intensity of statin therapy and renal outcome in chronic kidney disease: Results from the Korean Cohort Study for Outcome in Patients With Chronic Kidney Disease. Kidney Res Clin Pract 2020;39:93-102. [PMID: 32182639 DOI: 10.23876/j.krcp.20.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Campese VM. Dyslipidemia and progression of kidney disease: role of lipid-lowering drugs. Clin Exp Nephrol 2014;18:291-5. [PMID: 24535025 DOI: 10.1007/s10157-014-0934-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
20 Tziomalos K, Ganotakis ES, Gazi IF, Nair DR, Mikhailidis DP. Kidney function and estimated vascular risk in patients with primary dyslipidemia. Open Cardiovasc Med J 2009;3:57-68. [PMID: 19572030 DOI: 10.2174/1874192400903010057] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
21 Athyros VG, Kakafika AI, Papageorgiou AA, Pagourelias ED, Savvatianos SD, Elisaf M, Karagiannis A, Tziomalos K, Mikhailidis DP. Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease Patients. Open Cardiovasc Med J 2007;1:8-14. [PMID: 18949085 DOI: 10.2174/1874192400701010008] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
22 Choudhury D, Levi M. Kidney aging--inevitable or preventable? Nat Rev Nephrol 2011;7:706-17. [PMID: 21826079 DOI: 10.1038/nrneph.2011.104] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 4.5] [Reference Citation Analysis]
23 Esaki H, Tachi T, Goto C, Sugita I, Kanematsu Y, Yoshida A, Saito K, Noguchi Y, Ohno Y, Aoyama S, Yasuda M, Mizui T, Yamamura M, Teramachi H. Renoprotective Effect of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus. Front Pharmacol 2017;8:835. [PMID: 29187821 DOI: 10.3389/fphar.2017.00835] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
24 Baik SY, Kim H, Yang SJ, Kim TM, Lee SH, Cho JH, Lee H, Yim HW, Yoon KH, Kim HS. Long-term effects of various types of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on changes in glomerular filtration rate in Korea. Front Med 2019;13:713-22. [PMID: 30483915 DOI: 10.1007/s11684-018-0661-9] [Reference Citation Analysis]
25 Merx MW, Weber C. Sepsis and the heart. Circulation 2007;116:793-802. [PMID: 17698745 DOI: 10.1161/CIRCULATIONAHA.106.678359] [Cited by in Crossref: 318] [Cited by in F6Publishing: 139] [Article Influence: 21.2] [Reference Citation Analysis]
26 Kataria A, Trachtman H, Malaga-Dieguez L, Trasande L. Association between perfluoroalkyl acids and kidney function in a cross-sectional study of adolescents. Environ Health 2015;14:89. [PMID: 26590127 DOI: 10.1186/s12940-015-0077-9] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 7.4] [Reference Citation Analysis]
27 Samad Z, Sivak JA, Phelan M, Schulte PJ, Patel U, Velazquez EJ. Prevalence and Outcomes of Left-Sided Valvular Heart Disease Associated With Chronic Kidney Disease. J Am Heart Assoc 2017;6:e006044. [PMID: 29021274 DOI: 10.1161/JAHA.117.006044] [Cited by in Crossref: 25] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
28 Longenecker CT, Hileman CO, Funderburg NT, McComsey GA. Rosuvastatin preserves renal function and lowers cystatin C in HIV-infected subjects on antiretroviral therapy: the SATURN-HIV trial. Clin Infect Dis 2014;59:1148-56. [PMID: 25015912 DOI: 10.1093/cid/ciu523] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
29 Ho JE, Waters DD, Kean A, Wilson DJ, Demicco DA, Breazna A, Wun CC, Deedwania PC, Khush KK; TNT Investigators. Relation of improvement in estimated glomerular filtration rate with atorvastatin to reductions in hospitalizations for heart failure (from the Treating to New Targets [TNT] study). Am J Cardiol 2012;109:1761-6. [PMID: 22459310 DOI: 10.1016/j.amjcard.2012.02.019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
30 Athyros VG, Katsiki N, Tziomalos K, Karagiannis A. Preventing Cardio-renal Syndrome Rather than Treating It: Could Statins Play A Role? Open Cardiovasc Med J 2011;5:226-30. [PMID: 22207888 DOI: 10.2174/1874192401105010226] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
31 Rahman M, Baimbridge C, Davis BR, Barzilay J, Basile JN, Henriquez MA, Huml A, Kopyt N, Louis GT, Pressel SL, Rosendorff C, Sastrasinh S, Stanford C; ALLHAT Collaborative Research Group. Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Kidney Dis 2008;52:412-24. [PMID: 18676075 DOI: 10.1053/j.ajkd.2008.05.027] [Cited by in Crossref: 58] [Cited by in F6Publishing: 48] [Article Influence: 4.1] [Reference Citation Analysis]
32 McFarlane PA, Tobe SW, Culleton B. Improving outcomes in diabetes and chronic kidney disease: the basis for Canadian guidelines. Can J Cardiol 2007;23:585-90. [PMID: 17534468 DOI: 10.1016/s0828-282x(07)70806-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
33 Japanese Society of Nephrology. Evidence-based practice guideline for the treatment of CKD. Clin Exp Nephrol. 2009;13:537-566. [PMID: 19960305 DOI: 10.1007/s10157-009-0237-8] [Cited by in Crossref: 84] [Cited by in F6Publishing: 77] [Article Influence: 7.0] [Reference Citation Analysis]
34 Kuznik A, Mardekian J, Tarasenko L. Evaluation of cardiovascular disease burden and therapeutic goal attainment in US adults with chronic kidney disease: an analysis of national health and nutritional examination survey data, 2001-2010. BMC Nephrol 2013;14:132. [PMID: 23802885 DOI: 10.1186/1471-2369-14-132] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 4.9] [Reference Citation Analysis]
35 Gianella A, Nobili E, Abbate M, Zoja C, Gelosa P, Mussoni L, Bellosta S, Canavesi M, Rottoli D, Guerrini U, Brioschi M, Banfi C, Tremoli E, Remuzzi G, Sironi L. Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke-prone rats. Am J Pathol 2007;170:1165-77. [PMID: 17392157 DOI: 10.2353/ajpath.2007.060882] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 3.7] [Reference Citation Analysis]
36 Manns B, Tonelli M, Culleton B, Faris P, McLaughlin K, Chin R, Gooch K, McAlister FA, Taub K, Thorlacius L, Krause R, Kearns M, Hemmelgarn B; Alberta Kidney Disease Network. A cluster randomized trial of an enhanced eGFR prompt in chronic kidney disease. Clin J Am Soc Nephrol 2012;7:565-72. [PMID: 22344504 DOI: 10.2215/CJN.12391211] [Cited by in Crossref: 34] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
37 Klawitter J, Zafar I, Klawitter J, Pennington AT, Klepacki J, Gitomer BY, Schrier RW, Christians U, Edelstein CL. Effects of lovastatin treatment on the metabolic distributions in the Han:SPRD rat model of polycystic kidney disease. BMC Nephrol 2013;14:165. [PMID: 23902712 DOI: 10.1186/1471-2369-14-165] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
38 Deedwania PC, Stone PH, Fayyad RS, Laskey RE, Wilson DJ. Improvement in Renal Function and Reduction in Serum Uric Acid with Intensive Statin Therapy in Older Patients: A Post Hoc Analysis of the SAGE Trial. Drugs Aging 2015;32:1055-65. [PMID: 26625880 DOI: 10.1007/s40266-015-0328-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
39 Mathew RO, Rosenson RS, Lyubarova R, Chaudhry R, Costa SP, Bangalore S, Sidhu MS. Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease. Cardiovasc Drugs Ther 2021;35:479-89. [PMID: 32556851 DOI: 10.1007/s10557-020-07020-x] [Reference Citation Analysis]
40 Bae J, Hong N, Lee BW, Kang ES, Cha BS, Lee YH. Comparison of Renal Effects of Ezetimibe-Statin Combination versus Statin Monotherapy: A Propensity-Score-Matched Analysis. J Clin Med 2020;9:E798. [PMID: 32183405 DOI: 10.3390/jcm9030798] [Reference Citation Analysis]
41 Adeney KL, Siscovick DS, Ix JH, Seliger SL, Shlipak MG, Jenny NS, Kestenbaum BR. Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol. 2009;20:381-387. [PMID: 19073826 DOI: 10.1681/asn.2008040349] [Cited by in Crossref: 269] [Cited by in F6Publishing: 141] [Article Influence: 19.2] [Reference Citation Analysis]
42 de Boer IH, Astor BC, Kramer H, Palmas W, Seliger SL, Shlipak MG, Siscovick DS, Tsai MY, Kestenbaum B. Lipoprotein abnormalities associated with mild impairment of kidney function in the multi-ethnic study of atherosclerosis. Clin J Am Soc Nephrol 2008;3:125-32. [PMID: 18057305 DOI: 10.2215/CJN.03390807] [Cited by in Crossref: 43] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
43 O'Seaghdha CM, Perkovic V, Lam TH, McGinn S, Barzi F, Gu DF, Cass A, Suh I, Muntner P, Giles GG, Ueshima H, Woodward M, Huxley R; Asia Pacific Cohort Studies Collaboration. Blood pressure is a major risk factor for renal death: an analysis of 560 352 participants from the Asia-Pacific region. Hypertension 2009;54:509-15. [PMID: 19597042 DOI: 10.1161/HYPERTENSIONAHA.108.128413] [Cited by in Crossref: 40] [Cited by in F6Publishing: 16] [Article Influence: 3.1] [Reference Citation Analysis]
44 Esmeijer K, Dekkers OM, de Fijter JW, Dekker FW, Hoogeveen EK. Effect of different types of statins on kidney function decline and proteinuria: a network meta-analysis. Sci Rep 2019;9:16632. [PMID: 31719617 DOI: 10.1038/s41598-019-53064-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
45 Moisi MI, Rus M, Bungau S, Zaha DC, Uivarosan D, Fratila O, Tit DM, Endres L, Nistor-Cseppento DC, Popescu MI. Acute Coronary Syndromes in Chronic Kidney Disease: Clinical and Therapeutic Characteristics. Medicina (Kaunas) 2020;56:E118. [PMID: 32182690 DOI: 10.3390/medicina56030118] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
46 Sanguankeo A, Upala S, Cheungpasitporn W, Ungprasert P, Knight EL. Effects of Statins on Renal Outcome in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis. PLoS One 2015;10:e0132970. [PMID: 26151753 DOI: 10.1371/journal.pone.0132970] [Cited by in Crossref: 60] [Cited by in F6Publishing: 47] [Article Influence: 8.6] [Reference Citation Analysis]
47 Lee C, Park JT, Chang TI, Kang EW, Nam KH, Joo YS, Sung SA, Kim YH, Chae DW, Park SK, Ahn C, Oh KH, Yoo TH, Kang SW, Han SH. Low-density lipoprotein cholesterol levels and adverse clinical outcomes in chronic kidney disease: Results from the KNOW-CKD. Nutr Metab Cardiovasc Dis 2021:S0939-4753(21)00498-1. [PMID: 34893405 DOI: 10.1016/j.numecd.2021.09.037] [Reference Citation Analysis]
48 Haynes R, Lewis D, Emberson J, Reith C, Agodoa L, Cass A, Craig JC, de Zeeuw D, Feldt-Rasmussen B, Fellström B, Levin A, Wheeler DC, Walker R, Herrington WG, Baigent C, Landray MJ; SHARP Collaborative Group., SHARP Collaborative Group. Effects of lowering LDL cholesterol on progression of kidney disease. J Am Soc Nephrol 2014;25:1825-33. [PMID: 24790178 DOI: 10.1681/ASN.2013090965] [Cited by in Crossref: 101] [Cited by in F6Publishing: 43] [Article Influence: 12.6] [Reference Citation Analysis]
49 Scarpioni R, Ricardi M, Albertazzi V, Melfa L. Treatment of dyslipidemia in chronic kidney disease: Effectiveness and safety of statins. World J Nephrol 2012; 1(6): 184-194 [PMID: 24175258 DOI: 10.5527/wjn.v1.i6.184] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
50 Amarenco P, Callahan A, Campese VM, Goldstein LB, Hennerici MG, Messig M, Sillesen H, Welch KMA, Wilson DJ, Zivin JA. Effect of High-Dose Atorvastatin on Renal Function in Subjects With Stroke or Transient Ischemic Attack in the SPARCL Trial. Stroke 2014;45:2974-82. [DOI: 10.1161/strokeaha.114.005832] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 2.9] [Reference Citation Analysis]
51 Vogt L, Bangalore S, Fayyad R, Melamed S, Hovingh GK, DeMicco DA, Waters DD. Atorvastatin Has a Dose-Dependent Beneficial Effect on Kidney Function and Associated Cardiovascular Outcomes: Post Hoc Analysis of 6 Double-Blind Randomized Controlled Trials. J Am Heart Assoc 2019;8:e010827. [PMID: 31020900 DOI: 10.1161/JAHA.118.010827] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
52 Manns B, Hemmelgarn B, Tonelli M, Au F, Chiasson TC, Dong J, Klarenbach S; Alberta Kidney Disease Network. Population based screening for chronic kidney disease: cost effectiveness study. BMJ 2010;341:c5869. [PMID: 21059726 DOI: 10.1136/bmj.c5869] [Cited by in Crossref: 88] [Cited by in F6Publishing: 78] [Article Influence: 7.3] [Reference Citation Analysis]